Although promising results were obtained in a subset of MM patients treated with venetoclax, this activity is restricted to tumor clones with high BCL-2:MCL-1 and BCL-2:BCL-xL expression ratios as well as reduced electron transport chain activity [86, 87]. This evidence concerns the gene BCL2 and neoplasm.